Blood Pressure Management for Adults 75 Years and Older

Introduction to Blood Pressure Targets

The American College of Cardiology recommends targeting a blood pressure of <130/80 mmHg for most community-dwelling adults aged 75 and older with hypertension, with individualization based on frailty status 1, 2, 3

For robust, community-dwelling older adults (≥75 years), the target blood pressure is <130/80 mmHg, which reduces stroke and total serious cardiovascular events without increasing falls or orthostatic hypotension (high-certainty evidence for stroke reduction, moderate-certainty evidence for cardiovascular event reduction) 4
For frail older adults or those with high comorbidity burden, the target systolic blood pressure is 140-150 mmHg, with individualization based on frailty, comorbidity burden, and limited life expectancy 3
The International Society of Hypertension (ISH) guidelines recommend individualizing targets for elderly based on frailty, with a minimum goal of reducing blood pressure by at least 20/10 mmHg, ideally to 140/90 mmHg 1, 7, 8

Orthostatic hypotension should be monitored closely, with standing blood pressure measured at each visit, although intensive blood pressure control does not increase orthostatic hypotension risk in trials 4
Acute kidney injury incidence increases by 1.0-1.5% with intensive treatment, but is manageable with monitoring 6
Electrolyte abnormalities are more common with intensive treatment, requiring periodic laboratory monitoring 6
Falls and syncope risk is not increased with intensive blood pressure control in community-dwelling older adults 4

For non-Black patients aged ≥75, the first-line medication is a low-dose ACEI or ARB, with addition of a dihydropyridine calcium channel blocker (DHP-CCB) if needed, and progression to a thiazide-like diuretic if necessary 1, 2
For Black patients aged ≥75, the first-line medication is a low-dose ARB plus DHP-CCB or DHP-CCB plus thiazide-like diuretic 1, 2
Treatment principles for older adults include simplifying regimens with once-daily dosing and single-pill combinations, starting low and going slow with careful titration and monitoring, and achieving target within 3 months while monitoring for adverse effects 1, 2, 4, 7, 8

The recommendation for <130/80 mmHg in robust older adults is supported by high-certainty evidence for stroke reduction and moderate-certainty evidence for cardiovascular event reduction 4
The 2017 ACC/AHA guidelines provide the strongest recommendation (Class I, Level A evidence) for treating community-dwelling adults ≥65 years to <130 mmHg 4
The 2020 ISH guidelines emphasize individualization based on frailty rather than age alone 1, 2
The 2024 ESC guidelines align with intensive targets but add consideration for very frail patients 3